World Journal of Surgery

, Volume 30, Issue 5, pp 787–793

Does Familial Non-Medullary Thyroid Cancer Adversely Affect Survival?

  • Frederic Triponez
  • Mariwil Wong
  • Cord Sturgeon
  • Nadine Caron
  • David G. Ginzinger
  • Mark R. Segal
  • Electron Kebebew
  • Quan-Yang Duh
  • Orlo H. Clark
Article

Abstract

Background

Familial non-medullary thyroid cancer (FNMTC) is associated with a higher rate of multifocality and a higher recurrence rate than sporadic thyroid cancer. However, the effect of FNMTC on life expectancy is unknown.

Material and Methods

Using data from our FNMTC database, we calculated life expectancy and survival rates after diagnosis of FNMTC and compared the results with the rates for unaffected family members and for the standard US population. Overall life expectancy and survival rates were calculated using the Kaplan–Meier method. We compared patients from families with 2 affected members with patients from families with ≥3 affected members. We also compared patients diagnosed in a known familial setting (index cases and subsequent cases) with patients diagnosed before the familial setting was recognized.

Results

There were 139 affected patients with 757 unaffected family members. The mean age at diagnosis was 40.8 ± 13.9 years and the mean follow-up time was 9.4 ± 11.7 years. Ten patients died of thyroid cancer during follow-up. The life expectancy of patients with FNMTC was similar to that of their unaffected family members. Survival was significantly shorter for patients with 3 or more affected family members, for patients diagnosed before the familial setting was recognized, and for patients with anaplastic cancer.

Conclusions

Our results suggest that FNMTC may be more aggressive than sporadic thyroid cancer, particularly in families with 3 or more affected members. However, when recognized and treated appropriately, it does not significantly shorten the overall life expectancy of the affected patients.

References

  1. 1.
    Hemminki K, Li X. Familial risk of cancer by site and histopathology. Int J Cancer 2003;103(1):105–109CrossRefPubMedGoogle Scholar
  2. 2.
    Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994;86(21):1600–1608PubMedGoogle Scholar
  3. 3.
    Pal T, Vogl FD, Chappuis PO, et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab 2001;86(11):5307–5312CrossRefPubMedGoogle Scholar
  4. 4.
    Hemminki K, Eng C, Chen B. Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol 2005;90(10):5747–5753CrossRefGoogle Scholar
  5. 5.
    Brunaud L, Zarnegar R, Wada N, et al. Chromosomal aberrations by comparative genomic hybridization in thyroid tumors in patients with familial nonmedullary thyroid cancer. Thyroid 2003;13(7):621–629CrossRefPubMedGoogle Scholar
  6. 6.
    Sturgeon C, Clark OH. Familial nonmedullary thyroid cancer. Thyroid 2005;15(6):588–593CrossRefPubMedGoogle Scholar
  7. 7.
    Alsanea O, Clark OH. Familial thyroid cancer. Curr Opin Oncol 2001;13(1):44–51CrossRefPubMedGoogle Scholar
  8. 8.
    Charkes ND. On the prevalence of familial nonmedullary thyroid cancer. Thyroid 1998;8(9):857–858PubMedGoogle Scholar
  9. 9.
    Uchino S, Noguchi S, Kawamoto H, et al. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg 2002;26(8):897–902CrossRefPubMedGoogle Scholar
  10. 10.
    Grossman RF, Tu SH, Duh QY, et al. Familial nonmedullary thyroid cancer. An emerging entity that warrants aggressive treatment. Arch Surg 1995;130(8):892–897PubMedGoogle Scholar
  11. 11.
    Takami H, Ozaki O, Ito K. Familial nonmedullary thyroid cancer: an emerging entity that warrants aggressive treatment. Arch Surg 1996;131(6):676PubMedGoogle Scholar
  12. 12.
    Lupoli G, Vitale G, Caraglia M, et al. Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet 1999;353(9153):637–639CrossRefPubMedGoogle Scholar
  13. 13.
    Alsanea O, Wada N, Ain K, et al. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery 2000;128(6):1043–1050CrossRefPubMedGoogle Scholar
  14. 14.
    Loh KC, Lo JC, Greenspan FS, et al. Familial papillary thyroid cancer: a case report. Ann Acad Med Singapore 1997;26(4):503–506PubMedGoogle Scholar
  15. 15.
    Arias E. United States life tables, 2002. Natl Vital Stat Rep 2004;53(6):1–38Google Scholar
  16. 16.
    Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338(5):297–306CrossRefPubMedGoogle Scholar
  17. 17.
    Sherman SI. Thyroid carcinoma. Lancet 2003;361(9356):501–511CrossRefPubMedGoogle Scholar
  18. 18.
    Wu HS, Young MT, Ituarte PH, et al. Death from thyroid cancer of follicular cell origin. J Am Coll Surg 2000;191(6):600–606CrossRefPubMedGoogle Scholar
  19. 19.
    Links TP, van Tol KM, Jager PL, et al. Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer 2005;12(2):273–280CrossRefPubMedGoogle Scholar
  20. 20.
    Uchino S, Noguchi S, Yamashita H, et al. Detection of asymptomatic differentiated thyroid carcinoma by neck ultrasonographic screening for familial nonmedullary thyroid carcinoma. World J Surg 2004;28(11):1099–1102CrossRefPubMedGoogle Scholar
  21. 21.
    Maxwell EL, Hall FT, Freeman JL. Familial non-medullary thyroid cancer: a matched-case control study. Laryngoscope 2004;114(12):2182–2186CrossRefPubMedGoogle Scholar
  22. 22.
    Vriens MR, Sabanci U, Epstein HD, et al. Reliability of fine-needle aspiration in patients with familial nonmedullary thyroid cancer. Thyroid 1999;9(10):1011–1016PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2006

Authors and Affiliations

  • Frederic Triponez
    • 2
    • 4
  • Mariwil Wong
    • 1
  • Cord Sturgeon
    • 1
  • Nadine Caron
    • 1
  • David G. Ginzinger
    • 2
  • Mark R. Segal
    • 3
  • Electron Kebebew
    • 1
  • Quan-Yang Duh
    • 1
  • Orlo H. Clark
    • 1
  1. 1.Endocrine Surgical OncologyUCSF / Mount Zion Medical CenterSan FranciscoUSA
  2. 2.Advanced Research Technologies, Applied BiosystemsFoster CityUSA
  3. 3.Epidemiology and BiostatisticsUCSFSan FranciscoUSA
  4. 4.Thoracic and Endocrine SurgeryUniversity Hospital of GenevaGeneva 14Switzerland

Personalised recommendations